HUTCHMED Initiates Global Trial of HMPL-A830

Summary by AI BETAClose X

HUTCHMED has initiated a global Phase Ia clinical trial for its novel KRAS-EGFR-antibody conjugate therapy, HMPL-A830, in patients with solid tumors, with the first patient dosed in China on September 24, 2026. This first-in-class therapy aims to deliver a potent KRAS inhibitor directly to EGFR-expressing tumors, simultaneously blocking both signaling pathways to enhance efficacy and tolerability, addressing a significant unmet need for patients with KRAS-altered cancers like colorectal, pancreatic, and lung cancers. HUTCHMED Limited has granted GSK a subsidiary exclusive worldwide rights, excluding certain Asian territories, to develop and commercialize HMPL-A830, with HUTCHMED responsible for the global Phase I development.

Disclaimer*

UK 100

Latest directors dealings